J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-86, 2015.
DOI : 10.1016/S1470-2045(12)70137-7

K. Kim, D. Sinn, S. Jung, G. Gwak, Y. Paik et al., The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?, Liver International, vol.34, issue.10, 2016.
DOI : 10.1053/jhep.2001.27219

Y. Han, D. Choi, and J. Park, Cirrhotomimetic Type Hepatocellular Carcinoma Diagnosed After Liver Transplantation???Eighteen Months of Follow-up: A Case Report, Transplantation Proceedings, vol.40, issue.8, 2008.
DOI : 10.1016/j.transproceed.2008.07.012

S. Jakate, A. Yabes, D. Giusto, B. Naini, C. Lassman et al., Diffuse Cirrhosis-like Hepatocellular Carcinoma, The American Journal of Surgical Pathology, vol.34, issue.7, pp.935-976, 2010.
DOI : 10.1097/PAS.0b013e3181ddf52f

S. Mcevoy, C. Mccarthy, L. Lavelle, D. Moran, C. Cantwell et al., Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases, RadioGraphics, vol.33, issue.6, pp.1653-68, 2013.
DOI : 10.1148/rg.336125104

K. Okuda, T. Noguchi, Y. Kubo, Y. Shimokawa, M. Kojiro et al., A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver, pp.280-289, 1981.

S. Mittal and H. El-serag, Epidemiology of HCC: Consider the Population, J Clin Gastroenterol. 2013, vol.47, issue.0, pp.2-6

A. Befeler, D. Bisceglie, and A. , Hepatocellular carcinoma: Diagnosis and treatment, Gastroenterology, vol.122, issue.6, pp.1609-1628, 2002.
DOI : 10.1053/gast.2002.33411

M. Colombo, Screening for cancer in viral hepatitis. Clin Liver Dis, Feb, vol.5, issue.1, pp.109-131, 2001.

K. Hanazaki, S. Kajikawa, N. Koide, W. Adachi, and J. Amano, Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis, The American Journal of Gastroenterology, vol.35, issue.3, pp.1243-50, 2001.
DOI : 10.1016/S0002-9270(99)00913-2

E. Andorno, M. Salizzoni, R. Schieroni, D. Hemptinne, and B. , Role of serum alpha-fetoprotein in preand post-orthotopic liver transplantation (OLT) for malignant disease, J Nucl Med Allied Sci, vol.33, issue.3, pp.132-136, 1989.

P. Johnson and R. Williams, Serum Alpha-Fetoprotein Estimations and Doubling Time in Hepatocellular Carcinoma: Influence of Therapy and Possible Value in Early Detection, JNCI: Journal of the National Cancer Institute, vol.64, issue.6, pp.1329-1361, 1980.
DOI : 10.1093/jnci/64.6.1329

T. Urabe, S. Hayashi, S. Terasaki, M. Terada, E. Matusushita et al., An assessment of therapeutic effect of hepatocellular carcinoma by the serial changes in serum AFP value]. Nihon Shokakibyo Gakkai Zasshi, pp.100-108, 1990.

M. Tsai, J. Wang, C. Hung, K. Kee, Y. Y. Lee et al., Favorable ??-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation, Journal of Gastroenterology and Hepatology, vol.44, issue.2, pp.605-617, 2010.
DOI : 10.1002/hep.21408

P. Kneuertz, A. Demirjian, A. Firoozmand, C. Corona-villalobos, N. Bhagat et al., Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and Outcomes, Annals of Surgical Oncology, vol.53, issue.9, pp.2897-907, 2012.
DOI : 10.1002/hep.23725

A. Yopp, A. Mokdad, H. Zhu, J. Mansour, G. Balch et al., Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma, Annals of Surgical Oncology, vol.190, issue.Suppl 4, pp.1075-82, 2015.
DOI : 10.1007/978-3-642-16037-0_6

E. Liver, . Of-the, E. Cancer, R. , and T. Of, EASL?EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma, Journal of Hepatology, vol.56, issue.4, pp.908-951, 2012.

K. Sano, T. Ichikawa, U. Motosugi, H. Sou, A. Muhi et al., Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid???enhanced MR Imaging, Radiology, vol.261, issue.3, pp.834-878, 2011.
DOI : 10.1148/radiol.11101840

J. Choi, J. Lee, S. Kim, J. Yoon, J. Baek et al., Hepatocellular Carcinoma: Imaging Patterns on Gadoxetic Acid???enhanced MR Images and Their Value as an Imaging Biomarker, Radiology, vol.267, issue.3, pp.776-86, 2013.
DOI : 10.1148/radiol.13120775

N. Yu, V. Chaudhari, S. Raman, C. Lassman, M. Tong et al., CT and MRI Improve Detection of Hepatocellular Carcinoma, Compared With Ultrasound Alone, in Patients With Cirrhosis, Clinical Gastroenterology and Hepatology, vol.9, issue.2, pp.161-168, 2011.
DOI : 10.1016/j.cgh.2010.09.017

G. Dodd, D. Memel, R. Baron, L. Eichner, and L. Santiguida, Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus?, American Journal of Roentgenology, vol.165, issue.3, pp.573-580, 1995.
DOI : 10.2214/ajr.165.3.7645473

S. Raza, H. Jang, and T. Kim, Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound, Abdominal Imaging, vol.160, issue.6, pp.153-61, 2014.
DOI : 10.2214/ajr.160.6.8388621

M. Kanematsu, R. Semelka, P. Leonardou, M. Mastropasqua, and J. Lee, Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations, Journal of Magnetic Resonance Imaging, vol.217, issue.2, pp.189-95, 2003.
DOI : 10.1002/jmri.10336

A. Reynolds, A. Furlan, D. Fetzer, E. Sasatomi, A. Borhani et al., Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know, RadioGraphics, vol.35, issue.2, pp.371-86
DOI : 10.1148/rg.352140114

Y. Park, C. Lee, B. Kim, J. Lee, J. Choi et al., Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis, Magnetic Resonance Imaging, vol.31, issue.7, pp.1137-1179, 2013.
DOI : 10.1016/j.mri.2013.01.011

J. Bruix and M. Sherman, Management of hepatocellular carcinoma, Hepatology, vol.35, issue.5, pp.1020-1022, 2011.
DOI : 10.1016/0016-5085(88)90436-2

M. Kudo, O. Matsui, N. Izumi, H. Iijima, M. Kadoya et al., JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan, Liver Cancer, vol.3, issue.3-4, pp.3-4458, 2014.
DOI : 10.1159/000343875

M. Kudo, Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer, pp.85-95, 2015.

D. Mitchell, J. Bruix, M. Sherman, and C. Sirlin, LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions, Hepatology, vol.20, issue.Suppl. 1, pp.1056-65, 2015.
DOI : 10.1016/j.acra.2013.01.016

E. Caturelli, G. Ghittoni, P. Roselli, D. Palo, M. Anti et al., Fine needle biopsy of focal liver lesions: The hepatologist's point of view, Liver Transplantation, vol.199, issue.S2, pp.26-35, 2004.
DOI : 10.1148/radiology.199.3.8637995

A. Bravo, S. Sheth, and S. Chopra, Liver Biopsy, New England Journal of Medicine, vol.344, issue.7, pp.495-500, 2001.
DOI : 10.1056/NEJM200102153440706

G. Huang, J. Sheu, P. Yang, H. Lee, T. Wang et al., Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma ??? a study based on 420 patients, Journal of Hepatology, vol.25, issue.3, pp.334-342, 1996.
DOI : 10.1016/S0168-8278(96)80120-6

F. Durand, J. Regimbeau, J. Belghiti, A. Sauvanet, V. Vilgrain et al., Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma, Journal of Hepatology, vol.35, issue.2, pp.254-262, 2001.
DOI : 10.1016/S0168-8278(01)00108-8

B. Ohlsson, J. Nilsson, U. Stenram, M. Akerman, and K. Tranberg, Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours, British Journal of Surgery, vol.43, issue.6, 2002.
DOI : 10.1046/j.1365-2168.2002.02111.x

S. Katyal, J. Oliver, M. Peterson, J. Ferris, B. Carr et al., Extrahepatic Metastases of Hepatocellular Carcinoma, Radiology, vol.216, issue.3, pp.698-703, 2000.
DOI : 10.1148/radiology.216.3.r00se24698

S. Okazumi, K. Isono, K. Enomoto, T. Kikuchi, M. Ozaki et al., Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment, J Nucl Med, vol.33, issue.3, pp.333-342, 1992.

J. Bruix, M. Reig, and M. Sherman, Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma, Gastroenterology, vol.150, issue.4, pp.835-53, 2016.
DOI : 10.1053/j.gastro.2015.12.041

J. Llovet, C. Brú, and J. Bruix, Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Seminars in Liver Disease, vol.19, issue.03, pp.329-367, 1999.
DOI : 10.1055/s-2007-1007122

J. Marrero, R. Fontana, A. Barrat, F. Askari, H. Conjeevaram et al., Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort, Hepatology, vol.49, issue.4, pp.707-723, 2005.
DOI : 10.1080/13651820310015833

J. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane et al., Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-90, 2008.
DOI : 10.1056/NEJMoa0708857

J. Gollob, S. Wilhelm, C. Carter, and S. Kelley, Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway, Seminars in Oncology, vol.33, issue.4, 2006.
DOI : 10.1053/j.seminoncol.2006.04.002

L. Liu, Y. Cao, C. Chen, X. Zhang, A. Mcnabola et al., Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5, Cancer Research, vol.66, issue.24, pp.11851-11859, 2006.
DOI : 10.1158/0008-5472.CAN-06-1377

S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas et al., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nature Reviews Drug Discovery, vol.47, issue.10, pp.835-879, 2006.
DOI : 10.4161/cc.3.2.648

Y. Chang, J. Adnane, P. Trail, J. Levy, A. Henderson et al., Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models, Cancer Chemotherapy and Pharmacology, vol.64, issue.Suppl 2, pp.561-74, 2007.
DOI : 10.1007/s00280-006-0393-4

A. He and A. Goldenberg, Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations, Therapeutic Advances in Gastroenterology, vol.23, issue.6, 2013.
DOI : 10.1093/annonc/mdr584

URL : http://journals.sagepub.com/doi/pdf/10.1177/1756283X13498540

A. Cheng, Y. Kang, Z. Chen, C. Tsao, S. Qin et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009.
DOI : 10.1016/S1470-2045(08)70285-7

C. Cainap, S. Qin, W. Huang, I. Chung, H. Pan et al., Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.33, issue.2, pp.172-181, 2015.
DOI : 10.1200/JCO.2013.54.3298

A. Cheng, Y. Kang, D. Lin, J. Park, M. Kudo et al., Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.31, issue.32, pp.314067-75, 2013.
DOI : 10.1200/JCO.2012.45.8372

P. Johnson, S. Qin, J. Park, R. Poon, R. J. Philip et al., Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study, Journal of Clinical Oncology, vol.31, issue.28, pp.313517-313541, 2013.
DOI : 10.1200/JCO.2012.48.4410

A. Zhu, O. Rosmorduc, T. Evans, P. Ross, A. Santoro et al., SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.33, issue.6, 2014.
DOI : 10.1200/JCO.2013.53.7746

L. Rimassa, T. Pressiani, C. Boni, C. Carnaghi, E. Caremoli et al., A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. The Oncologist, pp.379-80, 2013.

M. Nakano, M. Tanaka, R. Kuromatsu, H. Nagamatsu, M. Satani et al., Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study, Oncotarget, vol.7, issue.39, 2016.
DOI : 10.18632/oncotarget.10794

Y. Kang, T. Yau, J. Park, H. Lim, T. Lee et al., Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma, Annals of Oncology, vol.26, issue.12, pp.2457-63, 2015.
DOI : 10.1093/annonc/mdv388

A. Miller, B. Hoogstraten, M. Staquet, and A. Winkler, Reporting results of cancer treatment. Cancer, pp.207-221, 1981.

E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, 2009.
DOI : 10.1016/j.ejca.2008.10.026

L. Fournier, S. Ammari, R. Thiam, and C. Cuénod, Crit??res de la r??ponse tumorale en imagerie??: RECIST, mRECIST, Cheson, Journal de Radiologie Diagnostique et Interventionnelle, vol.95, issue.7-8, 2014.
DOI : 10.1016/j.jradio.2014.03.024

J. Bruix, M. Sherman, J. Llovet, M. Beaugrand, R. Lencioni et al., Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-451, 2001.
DOI : 10.1016/S0168-8278(01)00130-1

R. Lencioni and J. Llovet, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, Feb, vol.30, issue.1, pp.52-60, 2010.
DOI : 10.1055/s-0030-1247132

URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0030-1247132.pdf

M. Kudo, K. Ueshima, S. Kubo, M. Sakamoto, M. Tanaka et al., Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version), Hepatology Research, vol.30, issue.1, pp.3-9, 2016.
DOI : 10.1055/s-0030-1247132

M. Lin, O. Pellerin, N. Bhagat, P. Rao, R. Loffroy et al., Quantitative and Volumetric EASL and RECIST: Feasibility of a Semi-automated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization (TACE), J Vasc Interv Radiol, 2012.

V. Tacher, M. Lin, R. Duran, H. Yarmohammadi, H. Lee et al., Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach, Radiology, vol.278, issue.1, pp.275-84, 2015.
DOI : 10.1148/radiol.2015142951

L. Mannelli, S. Kim, C. Hajdu, J. Babb, T. Clark et al., Assessment of Tumor Necrosis of Hepatocellular Carcinoma After Chemoembolization: Diffusion-Weighted and Contrast-Enhanced MRI With Histopathologic Correlation of the Explanted Liver, American Journal of Roentgenology, vol.193, issue.4, pp.1044-52, 2009.
DOI : 10.2214/AJR.08.1461

T. Namimoto, Y. Yamashita, S. Sumi, Y. Tang, and M. Takahashi, Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging., Radiology, vol.204, issue.3, pp.739-783, 1997.
DOI : 10.1148/radiology.204.3.9280252

S. Bonekamp, Z. Li, J. Geschwind, V. Halappa, C. Corona-villalobos et al., Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional Response Criteria, Radiology, vol.268, issue.2, 2013.
DOI : 10.1148/radiol.13122307

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721055/pdf

S. Bonekamp, P. Jolepalem, M. Lazo, M. Gulsun, A. Kiraly et al., Hepatocellular Carcinoma: Response to TACE Assessed with Semiautomated Volumetric and Functional Analysis of Diffusion-weighted and Contrast-enhanced MR Imaging Data, Radiology, vol.260, issue.3, 2011.
DOI : 10.1148/radiol.11102330

S. Bonekamp, V. Halappa, J. Geschwind, Z. Li, C. Corona-villalobos et al., Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part II. Response Stratification Using Volumetric Functional Criteria after Intraarterial Therapy, Radiology, vol.268, issue.2, 2013.
DOI : 10.1148/radiol.13121637

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721055/pdf

Z. Yuan, J. Zhang, H. Yang, X. Ye, L. Xu et al., Diffusion-Weighted MR Imaging of Hepatocellular Carcinoma: Current Value in Clinical Evaluation of Tumor Response to Locoregional Treatment, Journal of vascular and interventional radiology, 2016.
DOI : 10.1016/j.jvir.2015.10.003

I. Kamel, E. Liapi, D. Reyes, M. Zahurak, D. Bluemke et al., Unresectable Hepatocellular Carcinoma: Serial Early Vascular and Cellular Changes after Transarterial Chemoembolization as Detected with MR Imaging, Radiology, vol.250, issue.2, pp.466-73, 2009.
DOI : 10.1148/radiol.2502072222

C. Chen, C. Li, Y. Kuo, T. Jaw, D. Wu et al., Early Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization: Choline Levels and MR Diffusion Constants???Initial Experience, Radiology, vol.239, issue.2, pp.448-56, 2006.
DOI : 10.1148/radiol.2392042202

J. Chung, N. Naik, R. Lewandowski, J. Deng, M. Mulcahy et al., Diffusionweighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World journal of gastroenterology, pp.3161-3168, 2010.

B. Taouli, R. Johnson, C. Hajdu, M. Oei, M. Merad et al., Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR American journal of roentgenology, pp.795-800, 2013.
DOI : 10.2214/ajr.12.9798

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144815/pdf

D. Ippolito, P. Bonaffini, L. Ratti, L. Antolini, R. Corso et al., Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World journal of gastroenterology, pp.5993-6000, 2010.

A. Larson, D. Wang, B. Atassi, K. Sato, R. Ryu et al., Transcatheter Intraarterial Perfusion: MR Monitoring of Chemoembolization for Hepatocellular Carcinoma???Feasibility of Initial Clinical Translation, Radiology, vol.246, issue.3, pp.964-71, 2008.
DOI : 10.1148/radiol.2463070725

R. Gaba, D. Wang, R. Lewandowski, R. Ryu, K. Sato et al., Four-dimensional Transcatheter Intraarterial Perfusion MR Imaging for Monitoring Chemoembolization of Hepatocellular Carcinoma: Preliminary Results, Journal of Vascular and Interventional Radiology, vol.19, issue.11, pp.1589-95, 2008.
DOI : 10.1016/j.jvir.2008.08.010

D. Wang, J. B. Lewandowski, R. Ryu, R. Sato, K. Mulcahy et al., Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma, Journal of Magnetic Resonance Imaging, vol.34, issue.182, pp.1106-1122, 2010.
DOI : 10.2214/ajr.176.3.1760667

C. Hsu, Y. Shen, C. Yu, C. Hsu, F. Hu et al., Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil, Journal of Hepatology, vol.55, issue.4, pp.858-65, 2011.
DOI : 10.1016/j.jhep.2011.01.032

A. Zhu, D. V. Sahani, D. Duda, E. Di-tomaso, M. Ancukiewicz et al., Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study, Journal of Clinical Oncology, vol.27, issue.18, pp.3027-3062, 2009.
DOI : 10.1200/JCO.2008.20.9908

D. V. Sahani, T. Jiang, K. Hayano, D. Duda, O. Catalano et al., Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy, Journal of Hematology & Oncology, vol.6, issue.1, 2013.
DOI : 10.1200/JCO.2005.02.2574

K. Michielsen, D. Keyzer, F. Verslype, C. Dymarkowski, S. Van-malenstein et al., Pretreatment DCE-MRI for prediction of PFS in patients with inoperable HCC treated with TACE. Cancer Imaging, pp.114-114, 2011.

H. Choi, C. Charnsangavej, S. Faria, H. Macapinlac, M. Burgess et al., Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria, Journal of Clinical Oncology, vol.25, issue.13, pp.1753-1762, 2007.
DOI : 10.1200/JCO.2006.07.3049

R. Benjamin, H. Choi, H. Macapinlac, M. Burgess, S. Patel et al., We Should Desist Using RECIST, at Least in GIST, Journal of Clinical Oncology, vol.25, issue.13, pp.1760-1764, 2007.
DOI : 10.1200/JCO.2006.07.3411

Z. Weng, J. Ertle, S. Zheng, T. Lauenstein, S. Mueller et al., Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma, Oncol Lett, vol.6, issue.6, pp.1707-1719, 2013.

J. Edeline, E. Boucher, Y. Rolland, E. Vauléon, M. Pracht et al., Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma, Cancer, vol.24, issue.suppl 2, pp.147-56, 2012.
DOI : 10.1200/JCO.2005.03.6723

M. Ronot, M. Bouattour, J. Wassermann, O. Bruno, C. Dreyer et al., Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib, The Oncologist, vol.19, issue.4, pp.2014394-402
DOI : 10.1634/theoncologist.2013-0114

T. Arizumi, K. Ueshima, H. Takeda, Y. Osaki, M. Takita et al., Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma, Journal of Gastroenterology, vol.97, issue.12, pp.1578-87, 2014.
DOI : 10.1002/cncr.11111

I. Bargellini, A. Scionti, V. Mismas, G. Masi, C. Vivaldi et al., Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?, Oncology, vol.86, issue.4, pp.191-199, 2014.
DOI : 10.1159/000358599

J. Choi, D. Imagawa, P. Bhosale, P. Bhargava, T. Tirkes et al., Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib, Clinical and Molecular Hepatology, vol.20, issue.2, pp.218-240
DOI : 10.3350/cmh.2014.20.2.218

H. Choi, C. Charnsangavej, S. De-castro-faria, E. Tamm, R. Benjamin et al., A Quantitative Analysis Correlated with FDG PET Findings, American Journal of Roentgenology, vol.183, issue.6, 2004.
DOI : 10.2214/ajr.183.6.01831619

M. Gavanier, A. Ayav, C. Sellal, X. Orry, M. Claudon et al., CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1, European Journal of Radiology, vol.85, issue.1, 2016.
DOI : 10.1016/j.ejrad.2015.10.024

J. Chapiro, M. Lin, R. Duran, R. Schernthaner, and J. Geschwind, Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI, Expert Review of Anticancer Therapy, vol.21, issue.3, 2015.
DOI : 10.1016/j.acra.2013.11.006

H. Choi, C. Charnsangavej, S. Faria, C. Tamm, E. Benjamin et al., A Quantitative Analysis Correlated with FDG PET Findings, American Journal of Roentgenology, vol.183, issue.6, pp.1619-1647, 2004.
DOI : 10.2214/ajr.183.6.01831619